Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.660 +0.100 (+3.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 474,011
Open 2.590
Bid (Size) 2.620 (1)
Ask (Size) 2.700 (4)
Prev. Close 2.560
Today's Range 2.520 - 2.700
52wk Range 2.215 - 6.300
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Via ACCESSWIRE
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune. 
Via Benzinga

Performance

YTD
-36.52%
-36.52%
1 Month
-3.27%
-3.27%
3 Month
-16.61%
-16.61%
6 Month
-33.00%
-33.00%
1 Year
-51.19%
-51.19%

More News

Read More
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
Via ACCESSWIRE
CVAC Stock Earnings: CureVac Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
Via ACCESSWIRE
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Via ACCESSWIRE
Earnings Scheduled For November 12, 2024
Via Benzinga
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Via ACCESSWIRE
Insights into CureVac's Upcoming Earnings
Via Benzinga
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
Via ACCESSWIRE
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Via ACCESSWIRE
CureVac to Present at the 12th International mRNA Health Conference
Via ACCESSWIRE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Via ACCESSWIRE
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Via ACCESSWIRE
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
Via ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Via ACCESSWIRE
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Southwest Airlines Adopts a Poison Pill Plan: 7 Things to Know
Via InvestorPlace
Why Is DouYu (DOYU) Stock Up 44% Today?
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
GOEV Stock: Canoo Receives Fleet Order From Go2 Delivery
Via InvestorPlace
DM Stock Alert: Nano Dimension Is Scooping Up Desktop Metal for $183 Million
Via InvestorPlace
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Via Benzinga
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.